Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

[Background] Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results from the phase 1/2 MonumenTAL-1 study (ClinicalTrials.gov id...

ver descrição completa

Detalhes bibliográficos
Autores: Schinke, Carolina, Touzeau, Cyrille, Oriol, Albert, Mateos, Maria Victoria, Stevens, Don, Rasche, Leo, Qin, Xiang, Kato, Kelly, Bathija, Sacheeta, Katz, Eva G., Gries, Katharine S., Campagna, Michela, Masterson, Tara, Hilder, Brandi W., Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Tomlinson, Chalmer, Moreau, Philippe, San Miguel, Jesús F., Rodríguez-Otero, Paula, Chari, Ajai
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::66d1a728a5a493b1428f4129cb40eafa
Acesso em linha:http://hdl.handle.net/10261/426894
https://api.elsevier.com/content/abstract/scopus_id/105009955620
Access Level:Acceso aberto
Palavra-chave:bispecific antibody
health‐related quality of life
multiple myeloma
patient‐reported outcome measures
Descrição
Resumo:[Background] Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results from the phase 1/2 MonumenTAL-1 study (ClinicalTrials.gov identifiers NCT03399799 and NCT04634552). This study describes patient-reported outcomes (PROs) among patients who received talquetamab in MonumenTAL-1.

Registros relacionados